Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Neurocognitive Performance Related to Global Cognitive Functioning as Measured by Cognitive Composite Scores and Estimated IQ Scores

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy

What was measured

Global cognitive functioning was measured based on Cognitive Composite Scores from the Bayley III instrument for subjects \<3 years of age and on estimated IQ scores from the Stanford Binet V instrument for subjects ≥3 years of age. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.

Analysis population: Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group48
Intermediate-Risk Group111
High-Risk Group41

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Low-Risk Group39
Intermediate-Risk Group87
High-Risk Group38
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group88.617.6Not reportedNot reportedNot reported
Intermediate-Risk Group91.015.4Not reportedNot reportedNot reported
High-Risk Group87.422.3Not reportedNot reportedNot reported
Prior to Maintenance Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group33
Intermediate-Risk Group64
High-Risk Group18
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group91.116.8Not reportedNot reportedNot reported
Intermediate-Risk Group92.315.1Not reportedNot reportedNot reported
High-Risk Group94.819.0Not reportedNot reportedNot reported
Completion of Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group28
Intermediate-Risk Group44
High-Risk Group9
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group85.817.5Not reportedNot reportedNot reported
Intermediate-Risk Group93.415.3Not reportedNot reportedNot reported
High-Risk Group76.818.6Not reportedNot reportedNot reported
12 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group23
Intermediate-Risk Group35
High-Risk Group9
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group89.221.3Not reportedNot reportedNot reported
Intermediate-Risk Group89.915.6Not reportedNot reportedNot reported
High-Risk Group83.318.3Not reportedNot reportedNot reported
24 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group15
Intermediate-Risk Group36
High-Risk Group6
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group97.616.7Not reportedNot reportedNot reported
Intermediate-Risk Group89.419.0Not reportedNot reportedNot reported
High-Risk Group77.721.0Not reportedNot reportedNot reported
36 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group14
Intermediate-Risk Group31
High-Risk Group4
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group92.426.0Not reportedNot reportedNot reported
Intermediate-Risk Group89.916.2Not reportedNot reportedNot reported
High-Risk Group81.317.4Not reportedNot reportedNot reported
48 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group15
Intermediate-Risk Group30
High-Risk Group6
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group85.324.1Not reportedNot reportedNot reported
Intermediate-Risk Group91.318.4Not reportedNot reportedNot reported
High-Risk Group85.227.4Not reportedNot reportedNot reported
60 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group15
Intermediate-Risk Group22
High-Risk Group4
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group82.025.6Not reportedNot reportedNot reported
Intermediate-Risk Group85.317.9Not reportedNot reportedNot reported
High-Risk Group71.518.4Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.6
        value
        88.6
      2. group Id
        OG001
        spread
        15.4
        value
        91.0
      3. group Id
        OG002
        spread
        22.3
        value
        87.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        39
      2. group Id
        OG001
        value
        87
      3. group Id
        OG002
        value
        38
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.8
        value
        91.1
      2. group Id
        OG001
        spread
        15.1
        value
        92.3
      3. group Id
        OG002
        spread
        19.0
        value
        94.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        33
      2. group Id
        OG001
        value
        64
      3. group Id
        OG002
        value
        18
      units
      Participants
    title
    Prior to Maintenance Therapy
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.5
        value
        85.8
      2. group Id
        OG001
        spread
        15.3
        value
        93.4
      3. group Id
        OG002
        spread
        18.6
        value
        76.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        28
      2. group Id
        OG001
        value
        44
      3. group Id
        OG002
        value
        9
      units
      Participants
    title
    Completion of Therapy
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.3
        value
        89.2
      2. group Id
        OG001
        spread
        15.6
        value
        89.9
      3. group Id
        OG002
        spread
        18.3
        value
        83.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        23
      2. group Id
        OG001
        value
        35
      3. group Id
        OG002
        value
        9
      units
      Participants
    title
    12 Months Off Therapy
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.7
        value
        97.6
      2. group Id
        OG001
        spread
        19.0
        value
        89.4
      3. group Id
        OG002
        spread
        21.0
        value
        77.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        36
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    24 Months Off Therapy
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.0
        value
        92.4
      2. group Id
        OG001
        spread
        16.2
        value
        89.9
      3. group Id
        OG002
        spread
        17.4
        value
        81.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        14
      2. group Id
        OG001
        value
        31
      3. group Id
        OG002
        value
        4
      units
      Participants
    title
    36 Months Off Therapy
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        24.1
        value
        85.3
      2. group Id
        OG001
        spread
        18.4
        value
        91.3
      3. group Id
        OG002
        spread
        27.4
        value
        85.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        30
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    48 Months Off Therapy
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        25.6
        value
        82.0
      2. group Id
        OG001
        spread
        17.9
        value
        85.3
      3. group Id
        OG002
        spread
        18.4
        value
        71.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        22
      3. group Id
        OG002
        value
        4
      units
      Participants
    title
    60 Months Off Therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      48
    2. group Id
      OG001
      value
      111
    3. group Id
      OG002
      value
      41
    units
    Participants
description
Global cognitive functioning was measured based on Cognitive Composite Scores from the Bayley III instrument for subjects \<3 years of age and on estimated IQ scores from the Stanford Binet V instrument for subjects ≥3 years of age. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.
dispersion Type
Standard Deviation
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
MEAN
population Description
Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.
reporting Status
POSTED
time Frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy
title
Neurocognitive Performance Related to Global Cognitive Functioning as Measured by Cognitive Composite Scores and Estimated IQ Scores
type
SECONDARY
unit Of Measure
score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice